2,073
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

, ORCID Icon, , , ORCID Icon &
Pages 653-659 | Received 17 Jul 2019, Accepted 10 Sep 2019, Published online: 18 Sep 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Hasumati Rahalkar, Alan Sheppard & Sam Salek. (2022) Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance. Expert Review of Clinical Pharmacology 15:2, pages 215-236.
Read now
András Inotai & Zoltán Kaló. (2019) How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics & Outcomes Research 19:6, pages 627-632.
Read now

Articles from other publishers (5)

Ahmad Nader Fasseeh, Baher Elezbawy, Kareem Ahmed El-Fass, Mary GamaI, Ahmed Seyam, Noha Hayek, Nagwan Abdel Rahman, Sohir Abdelhamid, Nader Fasseeh, Amr Shafik Saad, Ahmed Elagamy, Akram Mahmoud, Amal Samir Sedrak, Khaled Elshazly, Mariam Eldebeiky, Monica Talaat, Noura Maher Mohamed, Rania Ahmed Abdelaziz, Remonda Refaat, Shaimaa Akeel, Sherif Abaza & Zoltán Kaló. (2023) Maximizing the benefits of using biosimilars in Egypt. Journal of Pharmaceutical Policy and Practice 16:1.
Crossref
Anat Fisher, Jason D. Kim & Colin R. Dormuth. (2023) Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology Research and Practice 2023, pages 1-13.
Crossref
Ruggero Lasala, Paolo Abrate, Andrea Zovi & Fiorenzo Santoleri. (2022) Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability. Therapeutic Innovation & Regulatory Science 57:2, pages 352-364.
Crossref
Tomas Tesar, Peter Golias, Lucia Masarykova, Paweł Kawalec & András Inotai. (2021) The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia. Frontiers in Pharmacology 12.
Crossref
Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert Selke, Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean MacBride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell & Bjorn Wettermark. (2021) Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. BioMed Research International 2021, pages 1-16.
Crossref